Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin Kaiser, Matthew Jenner, Andrew Hall et al.|Journal of Clinical Oncology|2023Cited by 114
Early phase clinical trials extension to guidelines for the content of statistical analysis plansVictoria Homer, Piers Gaunt, Samantha Hinsley et al.|BMJ|2022Cited by 67
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancerGerard Walls, Alastair Greystoke, Jamie B. Oughton et al.|Clinical and Translational Radiation Oncology|2020Cited by 34
MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Martin Kaiser, Debbie Sherratt et al.|BMJ Open|2021Cited by 27
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.Martin Kaiser, Matthew Jenner, Andrew Hall et al.|Journal of Clinical Oncology|2021Cited by 17